Remimazolam Versus Propofol for General Anesthesia Induction in Patients on Renin-angiotensin System Blockers Undergoing Robot-assisted Laparoscopic Prostatectomy

Prostate Tumor Clinical Trial

Official title: Remimazolam Versus Propofol for General Anesthesia Induction in Patients on Renin-angiotensin System Blockers Undergoing Robot-assisted Laparoscopic Prostatectomy: A Randomized Controlled Study

Status Not yet recruiting

Clinical Trial Summary

The investigators conduct a random assignment into either the remimazolam group or the propofol group. Depending on the group assignment, either remimazolam (0.2 mg/kg) or propofol (1.0 mg/kg) is administered. If necessary, additional doses of remimazolam (0.1 mg/kg) or propofol (0.5 mg/kg) are given. The standard anesthesia procedure of our institution is followed, and blood pressure data recorded during the surgery is analyzed (mean arterial pressure <65mmHg is defined as hypotension).

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Prostate Tumor
• Prostatic Neoplasms

• NCT number: NCT06093971
• Study type: Interventional
• Source: Yonsei University
• Contact: So Yeon Kim
• Phone: 82-2-2228-2429
• Email: KIMSY326@yuhs.ac
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 2023
• Completion date: September 2025